Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kell, Sherron
24  Ergebnisse:
Personensuche X
?
1

Effect of Concomitant Medications on the Safety and Efficac..:

LeWitt, Peter A. ; Verhagen Metman, Leo ; Rubens, Robert...
Clinical Neuropharmacology.  41 (2018)  2 - p. 47-55 , 2018
Link: https://doi.org/10.1097/..
 
?
2

Conversion to carbidopa and levodopa extended-release (IPX0..:

Tetrud, James ; Nausieda, Paul ; Kreitzman, David...
Journal of the Neurological Sciences.  373 (2017)  - p. 116-123 , 2017
Link: https://doi.org/10.1016/..
 
?
3

Dosing and efficacy of extended-release carbidopa-levodopa ..:

Gupta, Suneel ; Khanna, Sarita ; Kell, Sherron.
Neurology.  88 (2017)  16_supplement - p. , 2017
Link: https://doi.org/10.1212/..
 
?
4

Characteristics of Advanced Parkinson's Disease Patients Wh..:

Kreitzman, David ; Dhall, Rohit ; Kell, Sherron..
Neurology.  86 (2016)  16_supplement - p. , 2016
Link: https://doi.org/10.1212/..
 
?
5

Comparison of efficacy from phase 3 clinical trials of IPX0..:

Elmer, Lawrence ; Gil, Ramon ; Silver, Dee...
Neurology.  84 (2015)  14_supplement - p. , 2015
Link: https://doi.org/10.1212/..
 
?
6

Summary of safety from clinical trial experience with IPX06..:

Mark, Margery ; Dhall, Rohit ; Kreitzman, David...
Neurology.  84 (2015)  14_supplement - p. , 2015
Link: https://doi.org/10.1212/..
 
?
7

Long-Term Treatment with Extended-Release Carbidopa–Levodop..:

Waters, Cheryl H. ; Nausieda, Paul ; Dzyak, Lyudmila...
CNS Drugs.  29 (2015)  4 - p. 341-350 , 2015
Link: https://doi.org/10.1007/..
 
?
8

Comparison of safety from phase 3 clinical trials of IPX066..:

Dhall, Rohit ; Mark, Margery ; Kreitzman, David...
Neurology.  84 (2015)  14_supplement - p. , 2015
Link: https://doi.org/10.1212/..
 
?
9

Conversion to IPX066 from Standard Levodopa Formulations in..:

Nausieda, Paul A. ; Hsu, Ann ; Elmer, Lawrence...
Journal of Parkinson's Disease.  5 (2015)  4 - p. 837-845 , 2015
Link: https://doi.org/10.3233/..
 
?
10

Comparison of IPX066 with carbidopa–levodopa plus entacapon..:

Stocchi, Fabrizio ; Hsu, Ann ; Khanna, Sarita...
Parkinsonism & Related Disorders.  20 (2014)  12 - p. 1335-1340 , 2014
Link: https://doi.org/10.1016/..
 
?
11

IPX066 Dose Conversion from Immediate-Release Carbidopa-Lev..:

Hsu, Ann ; Khanna, Sarita ; Kell, Sherron..
Neurology.  82 (2014)  10_supplement - p. , 2014
Link: https://doi.org/10.1212/..
 
?
12

Randomized trial of IPX066, carbidopa/levodopa extended rel..:

Pahwa, Rajesh ; Lyons, Kelly E. ; Hauser, Robert A....
Parkinsonism & Related Disorders.  20 (2014)  2 - p. 142-148 , 2014
Link: https://doi.org/10.1016/..
 
?
13

Analysis of IPX066 Dosing Data in Advanced Parkinson's Dise..:

Hsu, Ann ; O'Connell, Martin ; Kell, Sherron.
Neurology.  80 (2013)  7_supplement - p. , 2013
Link: https://doi.org/10.1212/..
 
?
14

Long-Term Safety of IPX066 Extended-Release Carbidopa-Levod..:

Ellenbogen, Aaron ; Nausieda, Paul ; Pourcher, Emmanuelle...
Neurology.  80 (2013)  7_supplement - p. , 2013
Link: https://doi.org/10.1212/..
 
?
15

Long-Term Safety of IPX066 Extended-Release Carbidopa-Levod..:

Nausieda, Paul ; Rudzinska, Monika ; Kell, Sherron...
Neurology.  80 (2013)  7_supplement - p. , 2013
Link: https://doi.org/10.1212/..
 
1-15